Table 1 Causes for the treatment deficit for neglected diseases: Round I and II
From: Expert Delphi survey on research and development into drugs for neglected diseases
| Â | Â | % (n) | % (n) | % (n) | % (n) | % (n) | Â | Â |
|---|---|---|---|---|---|---|---|---|
| Â | Â | most important | important | unimportant | least important | no judgment | Total valid % (n) | Total N (Missing) |
No or insufficient sustainability of public funding for R&D for neglected diseases | Round I | 40,3% (48) | 47,9% (57) | 7,6% (9) | 0,8% (1) | 3,4% (4) | 100,0% (119) | 159 (40) |
| Â | Round II | 54,1% (33) | 41,0% (25) | 3,3% (2) | 1,6% (1) | 0,0% (0) | 100% (61) | 77 (16) |
No or inadequate direct public funding for research and development (R&D) for neglected diseases | Round I | 35,2% (44) | 60,0% (75) | 3,2% (4) | 0,0% (0) | 1,6% (2) | 100,0% (125) | 159 (34) |
| Â | Round II | 54,8% (34) | 40,3% (25) | 4,8% (3) | 0,0% (0) | 0,0% (0) | 100% (62) | 77 (15) |
No or inadequate incentives for the private sector to invest into R&D for neglected diseases | Round I | 33,9% (42) | 49,2% (61) | 8,9% (11) | 4,8% (6) | 3,2% (4) | 100,0% (124) | 159 (35) |
| Â | Round II | 41,9% (26) | 45,2% (28) | 8,1% (5) | 3,2% (2) | 1,6% (1) | 100% (62) | 77 (15) |
No or inadequate private sector investment into R&D for neglected diseases | Round I | 33,6% (42) | 58,4% (73) | 4,8% (6) | 0,8% (1) | 2,4% (3) | 100,0% (125) | 159 (34) |
| Â | Round II | 45,2% (28) | 40,3% (25) | 4,8% (3) | 8,1% (5) | 1,6% (1) | 100% (62) | 77 (15) |
No or inadequate access to effective drugs for neglected diseases | Round I | 33,1% (40) | 47,1% (57) | 9,1% (11) | 8,3% (10) | 2,5% (3) | 100,0% (121) | 159 (38) |
| Â | Round II | 41,0% (25) | 47,5% (29) | 4,9% (3) | 6,6% (4) | 0,0% (0) | 100% (61) | 77 (16) |
No or inadequate research infrastructure in countries with neglected diseases | Round I | 29,5% (36) | 55,7% (68) | 7,4% (9) | 6,6% (8) | 0,8% (1) | 100,0% (122) | 159 (37) |
| Â | Round II | 27,9% (17) | 60,7% (37) | 8,2% (5) | 3,3% (2) | 0,0% (0) | 100% (61) | 77 (16) |
No or ineffective drugs for neglected diseases | Round I | 20,5% (24) | 48,7% (57) | 15,4% (18) | 8,5% (10) | 6,8% (8) | 100,0% (117) | 159 (42) |
| Â | Round II | 30,0% (18) | 58,3% (35) | 8,3% (5) | 3,3% (2) | 0,0% (0) | 100% (60) | 77 (17) |
Disease-specific research difficulties (unknown etiology, lack of research material) | Round II | 4,9% (3) | 62,3% (38) | 18,0% (11) | 11,5% (7) | 3,3% (2) | 100% (61) | 77 (16) |
No or inadequate research coordination | Round II | 8,2% (5) | 49,2% (30) | 32,8% (20) | 6,6% (4) | 3,3% (2) | 100% (61) | 77 (16) |
Lack of awareness/visibility of neglected diseases | Round II | 32,8% (20) | 52,5% (32) | 13,1% (8) | 1,6% (1) | 0,0% (0) | 100% (61) | 77 (16) |
Lack of health-needs driven priority setting in public funding | Round II | 44,3% (27) | 50,8% (31) | 4,9% (3) | 0,0% (0) | 0,0% (0) | 100% (61) | 77 (16) |
No or inadequate health delivery infrastructure and staff in developing countries | Round II | 45,9% (28) | 41,0% (25) | 9,8% (6) | 1,6% (1) | 1,6% (1) | 100% (61) | 77 (16) |
Inadequate research priorities in private sector R&D | Round II | 48,4% (30) | 37,1% (23) | 11,3% (7) | 3,2% (2) | 0,0% (0) | 100% (62) | 77 (15) |
Poverty as reason for market failure (perception of no market for drugs, insufficient R&D) | Round II | 55,0% (33) | 35,0% (21) | 5,0% (3) | 3,3% (2) | 1,7% (1) | 100% (60) | 77 (17) |
Poverty as disease-proliferating factor (i.a. inadequate prevention, inadequate housing, lack of clean water) in endemic countries | Round II | 57,4% (35) | 32,8% (20) | 6,6% (4) | 3,3% (2) | 0,0% (0) | 100%(61) | 77 (16) |